Drug notes:
4 undisclosed programs Clin0 organ transplant, undisclosed
About:
ExCellThera is developing stem cell therapies to engineer various cell lines for hematological malignancies. Thousands of patients in need of stem cell transplants are in need of a donor and those that do get one, do not always respond. ExCellThera is addressing this problem through the development of novel, one-time curative cell therapies based on their proprietary UM171 technology. UM171 is a molecule with hematopoeitic stem cell expansion properties which can be used to expand the low number of stem cells found in cord blood. ExCellThera’s lead candidate cell therapy, ECT-001, is composed of UM171-expanded stem cells to treat blood diseases. Initial Phase I/II clinical trials have already been completed with promising results.